4.7 Article

Molecular Hallmarks of Ischemia with Non-Obstructive Coronary Arteries: The INOCA versus Obstructive CCS Challenge

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/jcm11061711

Keywords

non-obstructive CAD; ischemia with non-obstructive coronary artery (INOCA); chronic coronary syndromes (CCS); coronary microvascular dysfunction (CMD); biomarker; gene expression; precision medicine

Funding

  1. PRIN [2017WJBKKW_001]

Ask authors/readers for more resources

This study aimed to explore the biological characteristics of patients with Ischemia with Non-Obstructive Coronary Arteries (INOCA) and obstructive chronic coronary syndrome (ObCCS) in order to find specific markers for each clinical condition. The study found that certain molecules involved in adhesion, signaling, vascular motion, and inflammation were expressed at lower levels in INOCA patients compared to ObCCS patients.
Up to 4 million patients with signs of myocardial ischemia have no obstructive coronary artery disease (CAD). The absence of precise guidelines for diagnosis and treatment in non-obstructive CAD encourages the scientific community to fill the gap knowledge, to provide non-invasive and less expensive diagnostic tools. The aim of our study was to explore the biological profile of Ischemia with Non-Obstructive Coronary Arteries (INOCA) patients with microvascular dysfunction compared to patients presenting with obstructive chronic coronary syndrome (ObCCS) in order to find specific hallmarks of each clinical condition. We performed a gene expression array from peripheral blood mononuclear cells (PBMCs) isolated from INOCA (n = 18) and ObCCS (n = 20) patients. Our results showed a significantly reduced gene expression of molecules involved in cell adhesion, signaling, vascular motion, and inflammation in INOCA as compared to the ObCCS group. In detail, we found lower expression of Platelet and Endothelial Cell Adhesion Molecule 1 (CD31, p < 0.0001), Intercellular Adhesion Molecule-1 (ICAM1, p = 0.0004), Tumor Necrosis Factor (TNF p = 0.0003), Transferrin Receptor (TFRC, p = 0.002), and Vascular Endothelial Growth Factor A (VEGFA, p = 0.0006) in the INOCA group compared with ObCCS. Meanwhile, we observed an increased expression of Hyaluronidase (HYAL2, p < 0.0001) in INOCA patients in comparison to ObCCS. The distinct expression of molecular biomarkers might allow an early and non-invasive differential diagnosis between ObCCS and INOCA, improving clinical management and treatment options, in the era of personalized medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available